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Abstract
Background: Several markers have been proposed to predict the outcome of chronic lymphocytic leukemia (CLL) patients.
However, discordances exist between the current prognostic factors, indicating that none of these factors are totally perfect.
Methodology/Principal Findings: Here, we compared the prognostic power of new RNA-based markers in order to
construct a quantitative PCR (qPCR) score composed of the most powerful factors. ZAP70, LPL, CLLU1, microRNA-29c and
microRNA-223 were measured by real time PCR in a cohort of 170 patients with a median follow-up of 64 months (range
3-330). For each patient, cells were obtained at diagnosis and RNA was extracted from purified CD19 cells. The best markers
were included in a qPCR score, which was thereafter compared to each individual factor. Statistical analysis showed that all
five RNA-based markers can predict treatment-free survival (TFS), but only ZAP70, LPL and microRNA-29c could significantly
predict overall survival (OS). These three markers were thus included in a simple qPCR score that was able to significantly
predict TFS and OS by dividing patients into three groups (0/3, 1-2/3 and 3/3). Median TFS were .210, 61 and 24 months
(P,0.0001) and median OS were .330, 242 and 137 months (P,0.0001), respectively. Interestingly, TFS results were also
confirmed in Binet stage A patients (P,0.0001). When compared to other classical factors, this score displays the highest
univariate Cox hazard ratio (TFS: HR=9.45 and OS: HR=13.88) but also provides additional prognostic information.
Conclusions: In our hands, this score is the most powerful tool for CLL risk stratification at the time of diagnosis.
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Introduction
Within the past decade, several markers have been proposed to
predict the outcome of chronic lymphocytic leukemia (CLL)
patients [1] . This disease is characterized by an accumulation of B
cells and is greatly heterogeneous in terms of clinical course. Half
of the patients display an indolent and stable disease, whereas the
other half displays a very aggressive disease with poor outcome [2].
While the ‘‘old’’ parameters such as clinical stage (Rai [3] or Binet
[4]) are unable to prospectively distinguish early-stage CLL that
progresses rapidly to aggressive disease from disease destined to
remain in an early stage for an extended time, the ‘‘new’’
parameters described since 1999 have considerably improved
disease risk classification. One of the most important prognostic
molecular factors is the mutational status of the immunoglobulin
heavy chain region (IgVH). Indeed, patients presenting with an
unmutated IgVH had a worse outcome than patients with mutated
IgVH, who had a good prognosis [5,6]. However, this analysis is
laborious and costly as well as inaccessible for most clinical
laboratories. Therefore, in an effort to simplify this procedure,
several attempts have been made to replace this analysis with an
efficient surrogate marker. Numerous genes were suggested based
on gene expression profiles comparing IgVH mutated and
unmutated patients [7,8]. Of these, ZAP70 (zeta-associated
protein 70) and LPL (lipoprotein lipase) expression was associated
with IgVH status and with poor outcome, and their prognostic
significance has now been confirmed by several studies (reviewed
in [1]). Furthermore, accurate and standardized methods to
measure these two markers by quantitative real-time PCR (qPCR)
have been described [9,10]. Other RNA-based prognostic factors
such as CLLU1 [11], microRNA-29c (ormiR-29c) and microRNA-
223 (or miR-223) [12] have also been proposed. However, several
discordances exist between these RNA-based markers, indicating
that none of these prognostic factors is totally perfect to predict TFS
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e12780or OS. In addition, the use of only one factor could lead to the
misclassification of the patient, whereas a combination of factors
could reduce this risk. Managing the treatment course of CLL
patients cannot be planned without taking their prognosis into
account. Therefore, in the present study we aimed to construct a
molecular qPCR score composed of the best prognostic factors
among the five above-mentioned RNA-based markers in order to
improve CLL patient risk stratification at diagnosis. Furthermore,
because the majority of patients (70–80%) are diagnosed at an early
stage and an efficient prognostic factor should be able to identify
those patients with a higher risk of progressive disease at the time of
diagnosis, we also evaluated the developed score in newly diagnosed
stage A CLL patients. Finally, we compared this score to each
individual marker and also to the currently used prognostic factors
[IgVH mutational status, Binet stage, b2-microglobulin (b2-M),
soluble CD23 (sCD23), lymphocyte doubling time (LDT), CD38
molecule (CD38) and cytogenetic abnormalities]. The additional
power of this qPCR score was also tested in poor or good prognosis
subgroups defined by other prognostic markers.
Results
Patient characteristics
The main characteristics of this 170 patient cohort are shown in
Table 1. The male to female ratio was 1.7 and the median age at
diagnosis was 64 years (range 34-89), with 46% of patients aged
more than 65 years and 30% aged more than 70 years. Binet stage
distribution was 73, 18 and 9%, respectively, for Binet stage A, B
and C. The median TFS of this cohort was 76 months (range,
0.03–210 months), whereas the median OS was 242 months
(range, 0.5–330 months). The median follow-up was 64 months
(range 3–330). Of the total 170 patients, 84 patients (49%) received
a treatment, whereas only 24 patients (14%) died. Of the 124 Binet
stage A patients, 43 patients (35%) received a treatment, whereas
only 8 patients (6%) died. Of the 46 Binet stage B/C, 41 patients
(89%) received a treatment, whereas 16 patients (35%) died
Complete prognostic data were not available for all patients due to
a lack of biological material (Table 1). For Binet stages, ZAP70,
LPL, CLLU1, microRNA-29c and microRNA-223 expression,
clinical data were available for all of the 170 patients included in
this study. Incomplete data were available for IgVH mutational
status (77% of the patients), CD38 expression (95%), LDT (73%),
b2-M (94%), sCD23 (90%) and cytogenetic abnormalities (68%).
Prognostic power of individual markers: TFS and OS
analysis
All cut-offs were calculated using ROC curve analysis to
maximize the concordance with the IgVH mutational status and
are provided in Table 1. Although these cut-offs were not always
optimized for TFS/OS prediction, they were sufficient to observe
the following statistical differences: among our 170 patients, all
RNA-based tested markers (ZAP70, LPL, CLLU1, microRNA-
29c and microRNA-223) were able to significantly predict TFS,
whereas only ZAP70, LPL and microRNA-29c were significant
OS predictors as calculated by Kaplan-Meier curves (with log-
rank test) and univariate Cox regression after dichotomisation of
the data (Table 1 and Figure 1). The prognostic power of other
classical factors was also evaluated and is stated in Table 1.
Construction and prognostic evaluation of the qPCR
score
The aim of this study was to construct a score using a unique
and standardized technique in order to refine CLL prognosis
methods. To this end, we constructed a simple and easy qPCR
score by including the best individual prognostic factors, namely
ZAP70, LPL and microRNA-29c. Indeed, only these three
markers could significantly predict both TFS and OS. Further-
more, they are measurable by qPCR and thus no other techniques,
such as flow cytometry or FISH analysis, are needed. This qPCR
score varied from 0 to 3 according to the number of unfavorable
factors (i.e., low expression of miR-29c and high expression of
ZAP70 or LPL). The presence of a poor prognostic marker
corresponds to an increase of 1 unit in the final qPCR score. We
gave the same weight to all three factors. According to this qPCR
score, the patients were thus stratified into three groups: 0/3 (all
factors classified the patients in the favourable prognostic group),
3/3 (all factors classified the patients in the unfavourable
prognostic group) and finally 1-2/3 (at least one factor classified
patients in an unfavourable prognostic group). The hazard ratio
(HR) of these three groups (named 0, 0.5, and 1) was calculated by
univariate Cox analysis. In other words, HR represents the hazard
ratio between group 0/3 and 3/3 taking into account the
intermediate group such that 0/3,1–2/3,3/3. Patients with a
score of 0/3, 1–2/3, and 3/3 had a median TFS of .210, 60 and
24 months, respectively (HR=9.5, P,0.0001) and a median OS of
.330, 242 and 137 months, respectively (HR=13.9, P=0.0001)
(Figure 2). Finally, in Binet stage A patients (n=124), this score
remained relevant and significant for TFS. Patients with a score of
0/3, 1–2/3, and 3/3 had a median TFS of .210, 88 and 37
months, respectively (HR=8.2, P,0.0001). For the prediction of
OS, the hazard ratio remains significant (HR=7.4, P=0.0443),
but the median OS for each group could not be reached and were,
thus, not calculable due to a limited number of events (n=8)
(Figure 2). When only Binet Stage B/C were considered (n=46),
our score displays a significant HR for TFS (HR=5.5, P=0.0095)
and OS (HR=11.2, P=0.0265).
Additional impact of the qPCR score on other prognostic
factors
To evaluate the additional impact of our qPCR score, we
applied this score to good and poor prognostic subgroups defined
by the 12 prognostic factors stated in Table 2. We, thus, obtained
24 subgroups (12 of good and 12 of poor prognosis). We divided
each of these subgroups according to the qPCR score, and we
calculated the median TFS and the median OS for all of the
subgroups generated. The univariate Cox HR was calculated as
described above. Interestingly, we observed that this qPCR score
allowed the identification of patients with a higher median TFS or
OS in poor prognostic subgroups and of patients with lower TFS
or OS in good prognosis subgroups (Table 2). Some examples of
this additional power for TFS were illustrated by Kaplan-Meier
curves (performed in poor/good prognostic subgroups) (Figure 3).
The qPCR score was able to divide patients into subgroups
previously classified by RNA-based, flow cytometric, proliferation,
serum and cytogenetic prognostic markers. Independently from
the chosen subgroups, all patients with any poor or good
prognostic factors but with a score of 0/3 had a median TFS
.210 months (except Binet Stage B/C patients) and a median OS
.330 months. It should be noted that all HR0/3,1–2/3,3/3 were
significant for TFS prediction, but not for OS, probably because of
the limited number of events per subgroup. Therefore, we
analysed the impact of our qPCR score more globally. Each
TFS and OS for all of the poor prognosis subgroups and all of the
good prognosis subgroups were plotted together (Figure 4A–D). A
clear trend indicating a reduction of median TFS and OS was
observed, and a Kruskal-Wallis test demonstrated that this qPCR
score could find at least two distinct subgroups with significantly
different TFS [in good (P,0.0001) and poor (P,0.0001)
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subgroups]. Figure 4E–F forest plots also show qPCR strength
compared to the other analysed prognostic markers.
Discussion
The aim of this study was to propose a simple tool in order to
asses CLL prognosis at the time of diagnosis. In recent years, an
increasing number of studies have proposed scores or indexes
that are gradually replacing the use of monoparametric
prognostic markers [18–20]. Indeed, clinical stages such as
Binet [4] or Rai [3] suffer from great prognostic heterogeneity.
Furthermore, with the widespread of blood analysis 70–80% of
CLL patients are diagnosed at an early stage, limiting the utility
of this easy prognostic tool. New individual markers including
proliferation, surface, molecular and cytogenetic markers have
been proposed. However, several discordances exist between the
current prognostic factors, indicating that none of these factors
are optimal, and each of these prognostic factors alone has
limited utility in predicting TFS or OS. Therefore, a better risk
stratification for an individualized and tailored follow-up of the
patient is needed. In 2006, Zuchetto et al. constructed a scoring
system based on six surface expression molecules [19]. In 2007,
Wierda et al. proposed a prognostic index based on a large
number of patients that was composed of six variables, including
clinical parameters and proliferation markers such as beta-2-
microglobulin [18]. These two studies both used OS as the end
point but did not investigate TFS. In 2010, Kienle et al.
proposed a prognostic model based on gene expression markers
and concluded that this model could not replace the established
prognostic factors, but can improve TFS and OS prediction
[20]. All of these classifiers have some degree of complexity
because of the larger number of parameters and are, therefore,
not always practical for physicians. In our previous work, we
demonstrated that microRNAs (miR-29c and miR-223) could
also add prognostic information to classical factors (ZAP70 and
LPL) in a qPCR score that is able to classify patients into five
(for TFS) or three (for OS) groups with decreasing median TFS
or OS [12]. This score already used less parameters than other
scoring systems (with the advantage of using a single technique)
but had a weak prognostic power during the two first years after
diagnosis.
Figure 1. Kaplan-Meier survival curves for TFS/OS of RNA-based markers. TFS and OS were plotted using Kaplan-Meier methods, and
curves were compared with the log-rank test (n=170). ZAP70 (A and F), LPL (B and G), CLLU1 (C and H), microRNA-29c (D and I) and microRNA-223 (E
and J). All cut-offs were determined using ROC curve analysis. Further information can be found in Table 1.
doi:10.1371/journal.pone.0012780.g001
Figure 2. qPCR combining ZAP70, LPL and microRNA-29c stratifies CLL patients in terms of TFS and OS. TFS and OS, according to our
qPCR score, were plotted with Kaplan-Meier methods for all Binet stages (A and B) and only Binet stage A (C and D). Curves were compared with the
log-rank test (all Binet stages, n=170; Binet stage A, n=124). The hazard ratio (HR) was calculated with univariate Cox regression. Further information
can be found in Table 1.
doi:10.1371/journal.pone.0012780.g002
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PLoS ONE | www.plosone.org 7 September 2010 | Volume 5 | Issue 9 | e12780In the present work, we wanted to construct an easy tool for
clinicians to use with a minimum number of parameters and
without difficult calculations or interpretations, as was the case for
Binet stages. To this end, we first investigated RNA-based markers
by univariate Cox regression for TFS and OS prediction. In a
second step, we only included in our qPCR score markers, which
were significant TFS and OS univariate predictors (ZAP70, LPL
and microRNA-29c). ZAP70 and LPL have been well document-
ed in the literature, and their prognostic power is no longer
contested [1]. The prognostic value of microRNA-29c is less
validated but has been described by us and others [12,21]. These
three markers can all be accurately measured by real-time PCR
[9,10,12], an easily standardized and reproducible method. In
addition, a three parameters score including mRNA and
microRNA allows the analysis of different cellular mechanisms
underlying the observed clinical evolution. Indeed, ZAP70 has
been implicated in CLL cell migration [22,23], a process that is
particularly relevant in CLL biology [24]. LPL has linked
alterations of lipid metabolism with CLL pathogenesis [25,26].
MicroRNA-29c also reflects tumour burden, proliferation and
disease aggressiveness [12], thus providing information about the
stage of disease evolution at the time of diagnosis.
Compared to our preview study [12], the number of patients in
the current study was increased (60 patients were added to the 110
patients initial cohort [12]) and their follow-up was updated.
Surprisingly, microRNA-223 lost its prognostic power for OS
prediction and was, therefore, excluded from the new qPCR score.
It should be noted that the preview score including microRNA-223
remains significant in our 170 patient cohort, but the differences
between subgroups was less pronounced (data not shown).
Classification was, thus, improved (particularly during the first
two years after diagnosis) and was simplified down to three
subgroups: 0/3 (low risk), 1–2/3 (intermediate risk) and 3/3 (high
risk). The idea is very simple: when all three factors are concordant
in predicting patient evolution, the patient is classified into the low
risk or high risk subgroup, but if at least one of the three factors is
discordant the patient is included in the intermediate risk subgroup.
After 105 months of follow-up, only 30% of the patients with a 0/3
score required treatment, whereas 65% of the 1–2/3 group and
100% of the 3/3 group required treatment. Furthermore, after 28
years of follow-up, patients with a 3/3 score had a 10-fold higher
risk to require treatment and a 19-fold higher risk to die compared
to patients with a 0/3 score. We also observed that this qPCR score
permits the division of Binet stage A patients into three groups with
a .210, 88 and 37 month median TFS, indicating that this score is
an effective prognostic tool in early stage patients.
This qPCR score can clearly refine the prognostic power of old and
new prognostic factors. Our statistical analyses reveal that this score
allows the identification of patients with a worse prognosis or a less
indolent evolution defined by the other recently applied prognostic
factors. The qPCR score was able to refine CLL prognosis and
produce a significant univariate HR even when we applied this score to
IgVH mutational status-based subgroups (one of the most commonly
used factors), as shown in Table 2. Therefore, this tool could be an
interesting alternative for patient’s lacking this information because of
technical limitations. In addition, this score could divide patients in 3
subgroups while IgVH status only defined 2 subgroups. Similar results
have been observed for proliferation (sCD23, b-2M, LDT), surface
(CD38) or other RNA-based (CLLU1) markers. Cytogenetic abnor-
malities also represent a powerful prognosticator [17]. However,
cytogenetic data were only available for 68% of our cohort. Therefore,
Dohner’s classification was adapted and patients were only separated in
two groups. The distribution of patients with unfavourable cytogenetic
abnormalities was 26% (10/38), 46% (25/55) and 72% (16/22) for
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correlation has to be confirmed in a wider series, but our qPCR score
has already defined different prognostic subgroups within cytogenet-
ically favourable and unfavourable prognosis subgroups as stated in
Figure 3. One of the most important observations is that the patient
group with a score of 0/3 always had a TFS.210 months and an
OS.330 months independently of the status of the other classical
prognostic factors. An exception is made for Binet Stage B/C patients
with a score of 0/3 who had a median TFS of 85 months. However,
this value was calculated on only 2 cases. Finally, this score also
displayed the best univariate HR for TFS and OS suggesting that, in
our hands, this qPCR score is currently the most powerful molecular
indicator for determining the prognosis of CLL patients.
One of the disadvantages of this score is the use of ROC curve
analysis to fix the cut-off. Indeed, in comparison to our previous
study, some cut-off remains quite stable (ZAP70 and microRNA-
29c) while there is a substantial modification for LPL (which
changes from 6 to 15) and microRNA-223 (from 82 to 138). For
LPL, this modification only changes the status of 2 patients who
became negative in the present study. However, the new
calculated cut-off induced a status change of 24 patients for
microRNA-223. This indicates that the microRNA-223 cut-off
seems not to be stable and this can explain the lost of its prognostic
value for OS prediction in the extended cohort. This cut-off
instability is another argument for the exclusion of microRNA-223
from the present qPCR score. The determination of the optimal
cut-off is a recurrent problem in all prognostic studies using
continuous variables. The CD38 cut-off is a representative
example. Cut-offs of 7 [27], 20 [28] and 30% [6] are all found
in the literature. The use of ROC analysis is just a way to optimize
concordance with TFS and OS. Optimally, cut-off points should
be validated on a larger patient cohort. To be consistent in the
present study, we also applied the same procedure for the
determination of the other prognostic factor cut-offs.
The present study also has several strengths. First, the validity of
this cohort for this kind of analysis is suggested by a consistent
follow-up (median follow-up of 64 months with a maximum of 28
years) and the representative prognostic impact of other current
prognostic factors (Table 1). Second, we performed our analyses on
CD19
+ purified samples. This score reflected thus an intrinsic
characteristic of leukemic cells. A small number of studies used a
cohort of highly purified CD19 cells. This aspect of the study could
also be considered a negative point by others because of the so-
called difficult and laborious purification and the need for special
equipment. However, it should be noted that cell isolation using
magnetic beads is an easy and rapid (less than 30 min) method. This
Figure 3. qPCR can fine tune prognosis in good or poor prognostic subgroups. The qPCR score was applied to different subgroups
(previously divided by other prognostic factors). TFS curves are shown for LPL (A, F), CD38 (B, G), LDT (C, H), b2-M (D, I), and cytogenetic abnormalities
(E, J). The median TFS and patient numbers in the different groups are provided in Table 2. Groups of less than two patients are not represented in
this figure.
doi:10.1371/journal.pone.0012780.g003
Figure 4. Supplementary prognostic value of the qPCR score. Each prognostic factor was used to divide the patient cohort in two different
prognostic subgroups according to prognostic factors reported in Table 1. The qPCR score was then applied to all poor prognosis subgroups and
good prognosis subgroups. (A) and (B) show the median TFS and median OS of the good prognosis subgroups, whereas (C) and (D) show the median
TFS and median OS of the poor prognostic subgroups. The dotted line and error bar represent the mean and the SEM, respectively. Statistical
differences were assessed using the Kruskal-Wallis test. Parts (E) and (F) show forest plots comparing the univariate Cox HR of the qPCR score with
other prognostic factors for TFS and OS prediction, respectively. The hazard ratio (HR) of all variables was calculated by univariate Cox analysis and
plotted with the 95% Cl on this forest plot. More details can be found in Table 2.
doi:10.1371/journal.pone.0012780.g004
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is affordable enough to be obtained and installed in many routine
laboratories. Furthermore, the availability of this qPCR score could
be extended to non-specialized laboratories or those that are not
qPCR-equipped because lysed cells can be easily sent to other labs
at room temperature. Third, this model was confirmed in Binet
stage A patients, the principal patient group in need of better
prognostic tools. Fourth, this study was performed on samples
collected at diagnosis, which is the most important time for
prognostication. Fifth, our model was internally validated. Indeed,
even if the 170 patient cohort was divided and reduced to 31
patients (as was the case for the LDT,1 year patients), our score
was unaffected and remained a significant TFS predictor. However,
before this score can be used for further applications, an external
validation, ideally a prospective trial, should be performed.
For patients, prognostic information is also important in helping
them to plan their lives. For clinician scientists, this score may
provide insight into the biology of the disease because the exact
roles of ZAP70, LPL and microRNA-29c are not yet completely
elucidated. In conclusion, this qPCR score has powerful
prognostic value and is easily, accurately determined, and reduces
patient misclassification. This new prognostic tool could, thus,
facilitate discussion between physicians and patients and help to
identify patients who will require early therapy.
Methods
Ethics Statement
This study has been approved by the Bordet Institute Ethics
Committee and conducted according to the principles expressed in
the Declaration of Helsinki. All samples were collected after
written informed consent.
Patients, sample collection, and RNA extraction
Thisstudy analysed peripheral blood samples collected at the time
of diagnosis from 170 CLL patients (with informed consent) with a
typical CD19
+CD5
+CD23
+ phenotype and blood leukocyte counts
between 10610
3 and 250610
3 cells/mL. Table 1 summarizes other
patient features. Treatment-free survival (TFS) and overall survival
(OS) were calculated from the time of diagnosis until the date of first
treatment and the date of death, respectively. All deaths were CLL-
related. Peripheral blood mononuclear cells were isolated bydensity-
gradient centrifugation over Linfosep (Biomedics, Madrid, Spain). B
cells were purified with a CD19
+ magnetic bead system (Mid-
iMACS, Miltenyi Biotec, Bergish Gladbash, Germany), according to
the manufacturer’s instructions. Mean B cell purity was .99% as
measured by flow cytometry. Total RNA was extracted from
purified CD19
+ cells in a single step using TriPure Isolation Reagent
(Roche Applied Science, Vilvoorde, Belgium).
Assessment of RNA-based prognostic factors
We measured ZAP70, LPL, and CLLU1 expression by qPCR
as previously described [9,10,13]. ZAP70 and LPL were measured
using Power SYBRH Green PCR Master Mix and CLLU1
(cDNA1 transcript) with TaqMan MGB probe and TaqManH
Universal PCR Master Mix (Applied Biosystems, Rotterdam, The
Netherlands) because of the presence of different CLLU1
alternative transcripts. Expression levels were normalized against
cyclophilin A (PPI) gene. MicroRNA expression was measured
using the TaqMan microRNA quantitative PCR kit (Applied
Biosystems) as previously described [12] and normalized with the
endogenous control, RNU48 (purchased from Applied Biosys-
tems). RNA-based makers were expressed as the fold-change of the
target gene expression in the calibrator B lymphoid cell line
Namalwa (for ZAP70, LPL, microRNA-29c and microRNA-223)
or a pool of purified normal B cells (for CLLU1) because of the
absence of CLLU1 in the cell line. All primers have been
previously described [9,10,13]. The comparative DDCt method
was applied for data analysis.
Assessment of other prognostic factors
CD38 expression was assessed by flow cytometry, sCD23 and
b2-M by ELISA immunoassay, and IgVH gene mutational
analysis was performed as previously described [5,10,14,15].
LDT was assessed according to Montserrat et al. [16]. Classical
cytogenetics by standard karyotype analysis and additional
interphase FISH were performed to screen for most common
aberrations using Chromoprobe MultiprobeH - CLL System
(Cytocell, Amplitech, Compiegne, France). Patients were then
classified according to Do ¨hner’s recommendations [17].
Statistical analysis
We analysed ROC curves with GraphPad Prism 5.0 (Graph-
Pad Software) to determine the ZAP70, LPL, CLLU1, miR-29c,
miR-223, CD38, sCD23 and b2-M expression cut-off values that
best distinguished mutated and unmutated cases. TFS and OS
distributions were plotted using Kaplan-Meier estimates and were
compared using the log-rank test or the Cox regression hazard
ratio method for more than two subgroups. Univariate Cox
regression analysis evaluated the effects of the different prognostic
variables on TFS and/or OS. All tests were two-sided. An effect
was considered to be statistically significant at P,0.05. All analyses
were performed with SPSS 15.0 software.
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